Combining Targeted Therapy and Immunotherapy Improves Overall Survival in Patients with Anaplastic Thyroid Cancer
Researchers from The University of Texas MD Anderson Cancer Center demonstrated that anti-PD-L1 immunotherapy in combination with mutation-directed targeted therapy extended overall survival (OS) in patients with anaplastic thyroid carcinoma (ATC).
24-Oct-2024 11:00 AM EDT
Add to Favorites